Company profile
Iovance Biotherapeutics, Inc. Insider Trading
IOVAEvery SEC Form 4 insider trading filing for Iovance Biotherapeutics, Inc. (IOVA) since April 2023 — open-market buys and sells by directors and officers, option exercises, and cluster activity, updated as each filing is reported to the SEC. Why 2023?
- Exchange
- Nasdaq
- Sector
- Biological Products, (No Diagnostic Substances)
- CIK
- 0001425205
- Filings
- 139
- Insiders
- 14
- Last filing
- 2026-09-08
Activity summary
Recent insider activity is bullish. Over the last 30 days, 12 insiders purchased shares versus 6 sales. Buying was led by Frederick G Vogt.
Three year balance
Buy and sell value by quarter, Q4 23 to Q3 26. Iovance Biotherapeutics, Inc. insiders are net buyers across the period shown.
Bars below the rule are sales, above are purchases. Largest quarter on the chart is $48.3M.
90 day insight
Over the last 90 days, Iovance Biotherapeutics, Inc. insiders bought $0 (16 transactions) and sold $483K (8 transactions).
- Most active insider: Frederick G Vogt with 6 transactions totaling $204K.
- Largest single sale: $147K by Frederick G Vogt on Sep 1, 2026.
Activity skews bullish — buys outpace sales.
Insider Transactions
Sourced from SEC EDGAR Form 4 filings. Updated hourly.
| Date | Insider | Company | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Frederick G Vogt | IOVA | Option Exercise | 15,626 | — | — |
| Sep 8, 2026 | Raj K. Puri | IOVA | Option Exercise | 9,766 | — | — |
| Sep 8, 2026 | Frederick G Vogt | IOVA | Option Exercise | 15,626 | — | — |
| Sep 8, 2026 | Frederick G Vogt | IOVA | Tax Withholding | 6,638 | $8.70 | $58K |
| Sep 8, 2026 | Raj K. Puri | IOVA | Option Exercise | 9,766 | — | — |
45 more transactions hidden
Free account · No credit card required
Building something? Get API access →
Query this yourself
The same rows, over the API.
curl "https://api.form4api.com/v1/transactions?ticker=IOVA" \
-H "X-Api-Key: $KEY"Top insiders
By total value filed.
Institutional Ownership
Top 13F-HR holders of Iovance Biotherapeutics, Inc. as of 2026-06-30
Data source: quarterly 13F-HR filings — institutional holders report positions within 45 days of quarter end. Joined with insider activity above — see who's loading up institutionally while insiders are trading. Full 13F-HR API →